摘要
目的探讨羟乙基淀粉130/0.4用于中度低白蛋白血症胃癌患者术后胶体治疗的安全性。方法选择术后血清白蛋白在3.0g/dl至2.5g/dl的胃癌患者65例,分成羟乙基淀粉130/0.4(HES)组和20%人血白蛋白(HA)组,比较两组在白蛋白,凝血功能和肾功能,手术并发症及胶体治疗费用上的差异。结果两组患在白蛋白水平,凝血功能、肾功能,术后并发症上无统计学差异,胶体治疗费用有统计学差异。结论羟乙基淀粉130/0.4能安全有效的应用于中度低白蛋白血症胃癌患者术后的胶体治疗。
Objective To investigate the safety hydroxyethyl starch 130/0.4 in gastric cancer patients with hypoproteinemia after operation. Methods 65 gastric cancer patients with hypoproteinemia divided into two groups: HA group and HES group. Compared the effects on albumin,kidney function,function of blood coagulation, complications and cost. Results There was no significant difference on albumin,kidney function,function of blood coagulation and complications. The cost in HES group was significantly lower than HA group. Conclusion THe hydroxyethyl starch 130 /0. 4 is safe and effective in gastric cancer patients with hypoproteinemia after operation.
出处
《中国保健营养（下半月）》
2013年第4期864-865,共2页
China Health Care & Nutrition
